Capricor Therapeutics traded at $5.26 this Wednesday August 17th, increasing $0.16 or 3.14 percent since the previous trading session. Looking back, over the last four weeks, Capricor Therapeutics gained 20.09 percent. Over the last 12 months, its price rose by 33.84 percent. Looking ahead, we forecast Capricor Therapeutics to be priced at 4.86 by the end of this quarter and at 4.46 in one year, according to Trading Economics global macro models projections and analysts expectations.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Bioline Rx 1.67 -0.03 -1.74% -39.47%
Bluebird Bio 6.78 0.20 3.04% -62.52%
Capricor Therapeutics 5.26 0.16 3.14% 33.84%
Cytokinetics 50.57 -0.24 -0.47% 67.17%
Plus Therapeutics, Inc. 0.55 0.01 2.45% -74.13%
Geron 2.15 -0.07 -3.15% 72.00%
J&J 168.00 0.42 0.25% -5.19%
Lumos Pharma Inc. 8.70 -0.15 -1.69% -2.47%
Prothena 31.76 0.15 0.47% -45.56%
PTC Therapeutics 51.17 -0.69 -1.33% 35.30%
Sarepta Therapeutics 109.00 1.17 1.09% 45.33%
Vascular Biogenics 0.23 -0.003 -1.23% -88.79%
Immunic Inc. 5.02 -0.07 -1.38% -47.27%

Indexes Price Day Year
USND 12938 -164.43 -1.25% -10.93%

Capricor Therapeutics
Capricor Therapeutics, Inc. is a biotechnology company. The Company is focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of diseases. It consists of cell therapy program, including CAP-1002 with Duchenne muscular dystrophy program and CAP-1002 with COVID-19 (SARS-CoV-2) program. It also includes exosomes program, such as exosome-based vaccines, exosome-based therapeutics and CDC-Derived Exosomes (CAP-2003). Duchenne muscular dystrophy program has completed HOPE-2, a Phase II clinical trial in the United States with its product candidate.CAP-1002 is a cardiac cell derived therapy used to treat patients with late-stage Duchenne muscular dystrophy. The Company has received the United States Food and Drug Administration (FDA) acceptance of its investigational new drug (IND) application for a clinical study of CAP-1002 in patients with severe or critical COVID-19.